Solanezumab Terminated Phase 3 Trials for Alzheimer's Disease (AD) Treatment

IndicationsStatusPurposePhase
TerminatedTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT01127633Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease
NCT01900665Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo
NCT02760602A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease